Top

Journal of Cancer Research and Clinical Oncology

Published in:

01-05-2005 | Letter to the Editors

Reply concerning “Clinical evaluation of in vitro chemosensitivity testing: the example of uveal melanoma” by Terheyden et al. (2004)

Authors: P. Terheyden, E.-B. Bröcker, J. C. Becker

Published in: Journal of Cancer Research and Clinical Oncology | Issue 5/2005

Excerpt

We are very grateful for the critical and valuable discussion of our paper by Ian Cree and colleagues, even if their letter partially lacks the appropriate style of scientific discussions. Cree et al. mainly judge our trial from the laboratory point of view, which is justified in some aspects, but does not necessarily reflect the clinical situation. It is actually surprising that Cree and colleagues became upset when we tested their suggestion that “treosulfan and gemcitabine might be more active than other drugs” and observed rather discouraging clinical efficacy. …

Avril MF, Aamdal S, Grob JJ, et al (2004) Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study. J Clin Oncol 22:1118–1125

Eskelin S, Pyrhönen S, Hahka-Kemppinen M, Tuomaala S (2003) A prognostic model and staging for metastatic uveal melanoma. Cancer 97:465–475CrossRefPubMed

Flaherty LE, Liu PY, Unger J, Sondak VK (1997) Comparison of patient characteristics and outcome between a single-institution phase II trial and a cooperative-group phase II trial with identical eligibility in metastatic melanoma. Am J Clin Oncol 20:600–604

Pföhler C, Cree IA, Ugurel S, Kuwert C, et al (2003) Treosulfan and gemcitabine in metastatic uveal melanoma patients: results of a multicenter feasibility study. Anticancer Drugs 14:337–340CrossRefPubMed

Serrone L, Zeuli M, Sega FM, Cognetti F (2000) Dacarbacine-based chemotherapy for metastatic melanoma: thirty-year experience overview. J Exp Clin Cancer Res 19:21–34

Title: Reply concerning “Clinical evaluation of in vitro chemosensitivity testing: the example of uveal melanoma” by Terheyden et al. (2004)
Authors: P. Terheyden
E.-B. Bröcker
J. C. Becker
Publication date: 01-05-2005
Publisher: Springer-Verlag
Published in: Journal of Cancer Research and Clinical Oncology / Issue 5/2005
Print ISSN: 0171-5216
Electronic ISSN: 1432-1335
DOI: https://doi.org/10.1007/s00432-004-0631-2

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Reply concerning “Clinical evaluation of in vitro chemosensitivity testing: the example of uveal melanoma” by Terheyden et al. (2004)

Excerpt

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 5/2005

Combination treatment of CC531-lac-Z rat liver metastases by chemoembolization with pemetrexed disodium and gemcitabine

Characterization of the combined cellular survival effects of benzoquinone-ansamycins and ionizing radiation

Oral capecitabine plus subcutaneous interferon alpha in advanced squamous cell carcinoma of the skin

Expression of homeodomain protein CDX2 in gallbladder carcinomas

Analyses of minimal residual disease based on Flt3 mutations in allogeneic peripheral blood stem cell transplantation

New tumor necrosis factor-α-inducing protein released from Helicobacter pylori for gastric cancer progression

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page